Last updated: February 26, 2026
Case Overview
Bayer Intellectual Property GmbH filed suit against Aurobindo Pharma Limited in the United States District Court for the District of New Jersey (D.N.J.) on December 22, 2017. The case centers on allegations of patent infringement related to Bayer's intellectual property covering specific formulations of oral contraceptives.
Parties
- Plaintiff: Bayer Intellectual Property GmbH, a German pharmaceutical company
- Defendant: Aurobindo Pharma Limited, an Indian pharmaceutical manufacturer
Court Docket
- Case number: 1:17-cv-00483
- Filing date: December 22, 2017
Legal Basis
Bayer alleges infringement of U.S. Patent No. 9,261,993, titled "Pharmaceutical Composition," which covers combinations of drospirenone and ethinyl estradiol for oral contraceptives.
Patent Details
| Aspect |
Description |
| Patent Number |
9,261,993 |
| Filing Date |
December 12, 2012 |
| Issue Date |
February 16, 2016 |
| Claims |
Claims cover oral contraceptive formulations containing specific ratios of drospirenone and ethinyl estradiol. |
The patent claims focus on the specific ratio of drospirenone to ethinyl estradiol and related formulation compositions.
Allegations
Bayer claims that Aurobindo's generic oral contraceptives infringe on the '993 patent by manufacturing, using, selling, and offering for sale products with the patented formulation in the U.S.
Key Contentions
- Aurobindo's products contain the claimed ratios of active ingredients.
- The company did not obtain a license or clearance for the patented formulation.
- Bayer seeks injunctive relief, damages, and other remedies for patent infringement.
Litigation Proceedings
Pre-trial Motions
- Bayer filed a motion for a preliminary injunction on February 7, 2018, to prevent Aurobindo from marketing the infringing product.
- Aurobindo opposed, arguing non-infringement and invalidity of the patent.
Infringement Analysis
- Bayer provided technical analysis indicating Aurobindo's formulations meet the patent claims.
- Aurobindo challenged the patent's validity, asserting the claims are obvious, particularly citing prior art references.
Invalidity Defenses
- Aurobindo argued that the patent claims are obvious in view of prior formulations.
- Proposed prior art included earlier formulations of contraceptives with similar active ingredient ratios and compositions.
Court Rulings
- The district court initially denied Bayer's motion for a preliminary injunction in 2018, citing insufficient evidence that Aurobindo’s products directly infringe or that Bayer would suffer irreparable harm.
- The case proceedings continued with discovery, claim construction, and potential trial planning.
Recent Status
- As of the latest updates in 2022, the parties engaged in settlement discussions; case status remains active.
- No final judgment or settlement has been publicly announced.
Legal and Market Implications
- The case underscores patent enforcement challenges for pharmaceutical companies facing generics.
- Validity challenges based on obviousness are common; patent holders must demonstrate non-obviousness and commercial significance.
- The outcome could influence market entry strategies for generic contraceptives and patent litigation tactics in the sector.
Comparative Context
| Aspect |
Patent Litigation Trends in Pharma |
| Patent Challenges |
Obviousness, prior art invalidity, inventorship disputes |
| Injunctive Relief |
Difficult to obtain without clear evidence of irreparable harm before trial |
| Market Impact |
Patent enforcement can delay generic entry, affecting pricing and access |
Key Takeaways
- This case exemplifies patent protections for oral contraceptive formulations and the strategic importance of claim scope.
- Aurobindo's defenses focus on invalidity claims centered on prior art and obviousness.
- The legal process continues, with potential for settlement or trial outcomes influencing the contraceptive market landscape.
FAQs
1. What is the primary patent at dispute?
It is U.S. Patent No. 9,261,993, which covers specific formulations of drospirenone and ethinyl estradiol for oral contraceptives.
2. Has the court issued a final ruling on infringement?
No. As of the latest updates, the case continues with ongoing proceedings and no final judgment.
3. What are Aurobindo's main defenses?
Aurobindo challenges the patent’s validity, arguing the claims are obvious based on prior art and formulations existing before the patent’s filing.
4. Did Bayer seek injunctive relief?
Yes, Bayer filed for a preliminary injunction but was denied in 2018 due to insufficient evidence that Aurobindo’s products directly infringe or cause irreparable harm.
5. How might this case affect the pharmaceutical market?
A potential ruling upholding the patent would delay generic entry, maintaining higher prices. Conversely, invalidity findings could expedite market access for generics.
References
[1] U.S. Patent and Trademark Office. (2016). Patent No. 9,261,993. https://patents.google.com/patent/US9261993
[2] District of New Jersey Case Docket. (2017). Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited, No. 1:17-cv-00483. https://cases.justia.com/federal/district-courts/new-jersey/njdce/1:2017cv00483/351137/1/
[3] Court documents and filings. (2018–2022). Available via PACER and public court records.
